Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Outcomes Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

Mohammad Ahsen Soomro, Shebli Atrash, Aliya Rashid, William Wesson, Hamza Hashmi, Aimaz Afrough, Barry S. Skikne, Forat Lutfi, Muhammad Umair Mushtaq, Al-Ola Abdallah, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6900.

https://doi.org/10.1182/blood-2023-180306

Published: 2023

Journal Articles

Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure

Forat Lutfi, Briha Ansari, Afraah Hawa, Al-Ola Abdallah, Zubair Shah, Andre Khazak, Hussam Hawamdeh, Marc S. Hoffmann, Muhammad Umair Mushtaq, William Wesson, Aliya Rashid, Maggie Nelson, Leyla Shune, Sunil Abhyankar, Joseph P McGuirk, Charles Porter, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6916.

https://doi.org/10.1182/blood-2023-188031

Published: 2023

Journal Articles

Comparison of Biosimilar Filgrastim (Nivestym) Versus Originator Filgrastim (Neupogen) for Peripheral Blood Stem Cell Mobilization for Allogeneic Hematopoietic Stem Cell Transplantation

Moazzam Shahzad, Joe S. Al-Ramahi, Muhammad Kashif Amin, Muhammad Fareed Khalid, Shaun DeJarnette, Zahra Mahmoudjafari, Maggie Nelson, Riley Hastings, Haitham Abdelhakim, Forat Lutfi, Nausheen Ahmed, Rajat Bansal, Leyla Shune, Al-Ola Abdallah, Anurag K. Singh, Sunil Abhyankar, Joseph P McGuirk, Muhammad Umair Mushtaq

Blood (2023) 142 (Supplement 1): 3523.

https://doi.org/10.1182/blood-2023-185652

Published: 2023

Journal Articles

The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma

Aroog Khaliq, William Wesson, Emerson Logan, Carine Tabak, Aliya Rashid, Razan Mansour, Muhammad Umair Mushtaq, Joseph P McGuirk, Hamza Hashmi, Mehdi Hamadani, Al-Ola Abdallah, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 2344.

https://doi.org/10.1182/blood-2023-179409

Published: 2023

Journal Articles

The GLAMM1 Study - Global Access to Myeloma Medications: Potential Barriers to Chimeric Antigen Receptors (CART) and T-Cell-Engaging Bispecific Antibodies (TCE) Globally

Rawan Atallah, Yara Shatnawi, Aytaj Mammadzadeh, Shahrukh K Hashmi, Shabeeha K Rana, Muhammad Umair Mushtaq, Benlazar Mohamed, Nihar Desai, Thiago Xavier Carneiro, Rakesh Popat, Joseph P McGuirk, Shebli Atrash, Zahra Mahmoudjafari, Al-Ola Abdallah, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 3327.

https://doi.org/10.1182/blood-2023-179050

Published: 2023

Journal Articles

Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naïve Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics

Jordan Snyder, Razan Mansour, Aytaj Mammadzadeh, Hamza Hashmi, Aimaz Afrough, Omar Alkharabsheh, Barry Paul, Shebli Atrash, Muhammad Umair Mushtaq, Barry S. Skikne, Nausheen Ahmed, Al-Ola Abdallah

Blood (2023) 142 (Supplement 1): 1985.

https://doi.org/10.1182/blood-2023-187487

Published: 2023

Journal Articles

Trends in Access to Cellular Therapies in Multiple Myeloma (TACTUM): Perspectives of Treating Versus Referring Physicians

Rawan Atallah, Md Saiful Islam Saif, Danai Dima, Anuj Shrestha, Faiz Anwer, Muhammad Umair Mushtaq, Forat Lutfi, Leyla Shune, Hamza Hashmi, Siddhartha Ganguly, Joseph P McGuirk, Shebli Atrash, Al-Ola Abdallah, Rahul Banerjee, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6678.

https://doi.org/10.1182/blood-2023-181218

Published: 2023

Journal Articles

Outcomes after Bone Marrow Versus Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation

Joe S. Al-Ramahi, Moazzam Shahzad, Muhammad Kashif Amin, Shaun DeJarnette, Maggie Nelson, Forat Lutfi, Nausheen Ahmed, Haitham Abdelhakim, Rajat Bansal, Leyla Shune, Al-Ola Abdallah, Anurag K. Singh, Sunil Abhyankar, Joseph P McGuirk, Muhammad Umair Mushtaq

Blood (2023) 142 (Supplement 1): 7028.

https://doi.org/10.1182/blood-2023-185209

Published: 2023

Journal Articles

Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis

Muhammad Kashif Amin, Moazzam Shahzad, Joe S. Al-Ramahi, Shaun DeJarnette, Forat Lutfi, Nausheen Ahmed, Haitham Abdelhakim, Rajat Bansal, Leyla Shune, Al-Ola Abdallah, Anurag K. Singh, Sunil Abhyankar, Joseph P McGuirk, Muhammad Umair Mushtaq

Blood (2023) 142 (Supplement 1): 2242.

https://doi.org/10.1182/blood-2023-182521

Published: 2023

Journal Articles

Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant

Aytaj Mammadzadeh, Yara Shatnawi, Rawan Atallah, Benlazar Mohamed, Nihar Desai, Shahrukh K Hashmi, Thiago Xavier Carneiro, Hira Shaikh, Christopher Strouse, Rakesh Popat, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 4727.

https://doi.org/10.1182/blood-2023-185151

Published: 2023

Journal Articles

BCMA Re-Emergence As a Prognostic Indicator of Clinical Relapse after Chimeric Antigen Receptor T-Cell Therapy (CART) in Multiple Myeloma

Aliya Rashid, William Wesson, Forat Lutfi, Muhammad Umair Mushtaq, Joseph P McGuirk, Al-Ola Abdallah, Wei Cui, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6801.

https://doi.org/10.1182/blood-2023-182126

Published: 2023

Journal Articles

Balancing Monitoring and Access: Optimal Duration of Monitoring for CD19 and BCMA CART Recipients for Lymphoma and Myeloma

William Wesson, Aliya Rashid, Md Saiful Islam Saif, Emerson Logan, Carine Tabak, Mary McGann, James A Davis, Liz Hazlett, Forat Lutfi, Muhammad Umair Mushtaq, Al-Ola Abdallah, Marc S. Hoffmann, Hamza Hashmi, Joseph P McGuirk, Mehdi Hamadani, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6914.

https://doi.org/10.1182/blood-2023-182872

Published: 2023

Journal Articles

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Nirali N. Shah, Jacques Azzi, Brenda W Cooper, Abhinav Deol, John DiPersio, Divya Koura, Brian McClune, Lori S. Muffly, Muhammad Umair Mushtaq, Rupa Narayan, Hyung Chan Suh, Gregory Yanik, Sritama Nath, Jennifer Whangbo, Guenther Koehne

Blood (2023) 142 (Supplement 1): 4862.

https://doi.org/10.1182/blood-2023-180990

Published: 2023

Journal Articles

Vdpace As Salvage Therapy in Triple Class Relapse/Refractory Multiple Myeloma

Priyanka Venkatesh, Sara Shatnawi, Yara Shatnawi, Hira Shaikh, Christopher Strouse, Shebli Atrash, Muhammad Umair Mushtaq, Nausheen Ahmed, Zahra Mahmoudjafari, Al-Ola Abdallah, Leyla Shune

Blood (2023) 142 (Supplement 1): 6694.

https://doi.org/10.1182/blood-2023-187652

Published: 2023

Journal Articles

Cardiovascular Complications of CD 19 Chimeric Antigen Receptor-T Cell Therapy: A Systematic Review

Moazzam Shahzad, Farrukh Munir, Junaid Khan, Muhammad Fareed Khalid, Sakina Abbas, Hafiza Wajeeha Javaid, Suneeba Javed Chattha, Mamoon Ahmed, Muhammad Salman Faisal, Iqra Anwar, Sibgha Gull Chaudhary, Muhammad Umair Mushtaq

Blood (2022) 140 (Supplement 1): 12768–12769.

https://doi.org/10.1182/blood-2022-157470

Published: 2022

Journal Articles

Outcomes with Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

Moazzam Shahzad, Qamar Iqbal, Sara J Zaidi, Amna Y Shah, Reem Sulaiman, Mamoon Ahmed, Ammad Naeem, Sorosh Daud, Iqra Anwar, Sibgha Gull Chaudhary, Peiman Hematti, Sunil H Abhyankar, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2022) 140 (Supplement 1): 12884–12885.

https://doi.org/10.1182/blood-2022-155832

Published: 2022

Journal Articles

Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients

Muhammad Umair Mushtaq, Joe S Al-Ramahi, Kevin S Li, Moazzam Shahzad, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Rajat Bansal, Haitham Abdelhakim, Leyla O. Shune, Anurag K. Singh, Sunil H Abhyankar, Joseph P. McGuirk

Blood (2022) 140 (Supplement 1): 10481–10483.

https://doi.org/10.1182/blood-2022-158716

Published: 2022

Journal Articles

Outcomes with Eltrombopag for Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

Moazzam Shahzad, Qamar Iqbal, Farrukh Munir, Sakina Abbas, Maheen Zaidi, Nimra Shafi, Muhammad Sohaib, Waleed Ahmed Mir, Iqra Anwar, Sibgha Gull Chaudhary, Maggie Nelson, Philip Lubanski, Zahra Mahmoudjafari, Peiman Hematti, Sunil H Abhyankar, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2022) 140 (Supplement 1): 12846–12847.

https://doi.org/10.1182/blood-2022-155813

Published: 2022

Journal Articles

Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in NPM1-Mutated Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

Ali Hussain, Moazzam Shahzad, Sakina Abbas, Junaid Khan, Ali Hassan Mushtaq, Muhammad Fareed Khalid, Murali Krishna Gurram, Iqra Anwar, Sibgha Gull Chaudhary, Peiman Hematti, Sunil H Abhyankar, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2022) 140 (Supplement 1): 12967–12968.

https://doi.org/10.1182/blood-2022-157094

Published: 2022

Journal Articles

Phlebotomy in Secondary Polycythemia: Does It Improve Clinical Symptoms? a Systematic Review

Mamoon Ahmed, Muhammad Fareed Khalid, Ayesha Abbas, Hira G. Shaikh, Mohammad Ammad-ud-din, Muhammad Umair Mushtaq, Moazzam Shahzad

Blood (2022) 140 (Supplement 1): 11050–11051.

https://doi.org/10.1182/blood-2022-170862

Published: 2022

NARROW

Outcomes Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure

Comparison of Biosimilar Filgrastim (Nivestym) Versus Originator Filgrastim (Neupogen) for Peripheral Blood Stem Cell Mobilization for Allogeneic Hematopoietic Stem Cell Transplantation

The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma

The GLAMM1 Study - Global Access to Myeloma Medications: Potential Barriers to Chimeric Antigen Receptors (CART) and T-Cell-Engaging Bispecific Antibodies (TCE) Globally

Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naïve Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics

Trends in Access to Cellular Therapies in Multiple Myeloma (TACTUM): Perspectives of Treating Versus Referring Physicians

Outcomes after Bone Marrow Versus Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation

Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis

Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant

BCMA Re-Emergence As a Prognostic Indicator of Clinical Relapse after Chimeric Antigen Receptor T-Cell Therapy (CART) in Multiple Myeloma

Balancing Monitoring and Access: Optimal Duration of Monitoring for CD19 and BCMA CART Recipients for Lymphoma and Myeloma

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Vdpace As Salvage Therapy in Triple Class Relapse/Refractory Multiple Myeloma

Cardiovascular Complications of CD 19 Chimeric Antigen Receptor-T Cell Therapy: A Systematic Review

Outcomes with Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients

Outcomes with Eltrombopag for Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in NPM1-Mutated Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

Phlebotomy in Secondary Polycythemia: Does It Improve Clinical Symptoms? a Systematic Review

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only